Glück Conviction Score™ ⓘ
PALI
PALISADE BIO, INC.
ⓘ
Eingeschränkte Aussagekraft — erst 66 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv: Schwach
Niedrig
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
49,4
27 neu, 30 erhöht, -64746K $ netto
Aktivist
37,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 1.99 | -13.9 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 1.75 | -2.6 % vs SMA200 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 1.86 | EMA50: 1.92 | |
| MACD-Histogramm | Bärisch | 10 % | -0.024 | Bearisch | |
| RSI(14) | Neutral | 10 % | 40.6 | Neutral (30–70) | |
| Stoch %K(14) | Bullisch | 5 % | 13.7 | Überverkauft | |
| ADX(14)+DI | Neutral | 10 % | 15.0 | +DI: 18.6 / −DI: 24.7 | |
| Z-Score(60) | Neutral | 5 % | -1.33 | In Range | |
| 52W-Position | Neutral | 5 % | 51.8 % | Hoch 2.80 / Tief 0.54 | |
| Bollinger(20,2σ) | Bullisch | 5 % | 18.2 % | Upper 2.16 / Mid 1.88 / Lower 1.61 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.0030 | R²=0.07 / annualisiert -38.2 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-12 | Jones Mitchell Lawrence | Officer, Chief Medical Officer | Open Market Sale | -1.989 | 1,75 | -3.480,75 | -49,6% | |
| 2026-02-12 | Finley John David | Director, Officer, CEO, CFO | Open Market Sale | -3.896 | 1,75 | -6.818,00 | -97,2% | |
| 2026-01-16 | Williams Donald Allen | Director | Open Market Purchase | 5.000 | 1,67 | 8.356,00 | +119,1% | |
| 2026-01-09 | Williams Donald Allen | Director | Open Market Purchase | 5.000 | 1,88 | 9.400,00 | +134,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| B Group, Inc. | 11.414.285 | 4.500.000 | 6.914.285 | 19.974.999 | Aufgestockt | +153,7% | |
| JANUS HENDERSON GROUP PLC | 10.689.452 | 10.540.334 | 149.118 | 18.759.988 | Aufgestockt | +1,4% | |
| Octagon Capital Advisors LP | 10.276.317 | 9.567.898 | 708.419 | 17.983.555 | Aufgestockt | +7,4% | |
| PERCEPTIVE ADVISORS LLC | 8.928.149 | 12.050.000 | -3.121.851 | 15.624.261 | Reduziert | -25,9% | |
| AMERIPRISE FINANCIAL INC | 8.711.385 | 6.911.237 | 1.800.148 | 15.244.925 | Aufgestockt | +26,0% | |
| Commodore Capital LP | 7.181.062 | 11.445.000 | -4.263.938 | 12.566.859 | Reduziert | -37,3% | |
| RA CAPITAL MANAGEMENT, L.P. | 7.124.116 | 7.124.116 | 0 | 12.467.203 | Unverändert | 0,0% | |
| Squadron Capital Management LLC | 4.500.000 | 0 | 4.500.000 | 10.575.000 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 5.785.189 | 5.092.562 | 692.627 | 10.124.081 | Aufgestockt | +13,6% | |
| STEMPOINT CAPITAL LP | 4.192.375 | 0 | 4.192.375 | 9.852.081 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 5.373.951 | 557.565 | 4.816.386 | 9.404.414 | Aufgestockt | +863,8% | |
| Eversept Partners, LP | 4.987.499 | 5.391.548 | -404.049 | 8.728.123 | Reduziert | -7,5% | |
| Boxer Capital Management, LLC | 4.799.875 | 4.799.875 | 0 | 8.399.781 | Unverändert | 0,0% | |
| MORGAN STANLEY | 4.551.533 | 4.142.446 | 409.087 | 7.965.183 | Aufgestockt | +9,9% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.500.000 | 4.500.000 | 0 | 7.875.000 | Unverändert | 0,0% | |
| GREAT POINT PARTNERS LLC | 3.405.757 | 0 | 3.405.757 | 5.960.075 | Neu | +100,0% | |
| BALYASNY ASSET MANAGEMENT L.P. | 3.270.845 | 325.367 | 2.945.478 | 5.723.979 | Aufgestockt | +905,3% | |
| FEDERATED HERMES, INC. | 3.136.607 | 0 | 3.136.607 | 5.489.062 | Neu | +100,0% | |
| Vivo Capital, LLC | 2.293.578 | 0 | 2.293.578 | 5.389.908 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 2.904.911 | 0 | 2.904.911 | 5.083.594 | Neu | +100,0% | |
| VANGUARD GROUP INC | 2.115.622 | 0 | 2.115.622 | 4.971.711 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 2.754.403 | 0 | 2.754.403 | 4.820.209 | Neu | +100,0% | |
| Vestal Point Capital, LP | 2.500.000 | 0 | 2.500.000 | 4.375.000 | Neu | +100,0% | |
| ORBIMED ADVISORS LLC | 2.333.000 | 1.871.420 | 461.580 | 4.082.750 | Aufgestockt | +24,7% | |
| ADAR1 Capital Management, LLC | 2.264.845 | 2.004.845 | 260.000 | 3.963.479 | Aufgestockt | +13,0% | |
| MILLENNIUM MANAGEMENT LLC | 2.103.353 | 294.486 | 1.808.867 | 3.680.868 | Aufgestockt | +614,2% | |
| HighVista Strategies LLC | 2.019.326 | 1.300.031 | 719.295 | 3.533.820 | Aufgestockt | +55,3% | |
| BlackRock, Inc. | 1.876.340 | 1.879.319 | -2.979 | 3.283.595 | Reduziert | -0,2% | |
| SPHERA FUNDS MANAGEMENT LTD. | 1.733.471 | 184.100 | 1.549.371 | 3.033.574 | Aufgestockt | +841,6% | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.546.240 | 1.565.452 | -19.212 | 2.707.443 | Reduziert | -1,2% | |
| RENAISSANCE TECHNOLOGIES LLC | 1.454.400 | 2.382.500 | -928.100 | 2.545.200 | Reduziert | -39,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.429.308 | 0 | 1.429.308 | 2.501.289 | Neu | +100,0% | |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1.231.414 | 664.087 | 567.327 | 2.154.975 | Aufgestockt | +85,4% | |
| UBS Group AG | 1.166.951 | 247.754 | 919.197 | 2.042.164 | Aufgestockt | +371,0% | |
| Propel Bio Management, LLC | 1.115.000 | 0 | 1.115.000 | 1.996.750 | Neu | +100,0% | |
| Aberdeen Group plc | 662.900 | 0 | 662.900 | 1.160.075 | Neu | +100,0% | |
| STATE STREET CORP | 636.197 | 643.997 | -7.800 | 1.113.345 | Reduziert | -1,2% | |
| Exome Asset Management LLC | 600.000 | 758.203 | -158.203 | 1.050.000 | Reduziert | -20,9% | |
| Creek Drive Management Group LLC | 540.000 | 307.500 | 232.500 | 945.000 | Aufgestockt | +75,6% | |
| Resolute Capital Asset Partners LLC | 400.000 | 0 | 400.000 | 940.000 | Neu | +100,0% | |
| SUPERSTRING CAPITAL MANAGEMENT LP | 367.103 | 0 | 367.103 | 862.692 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 411.772 | 10.495.252 | -10.083.480 | 720.601 | Reduziert | -96,1% | |
| JANE STREET GROUP, LLC | 410.761 | 343.686 | 67.075 | 718.832 | Aufgestockt | +19,5% | |
| Simplify Asset Management Inc. | 350.000 | 0 | 350.000 | 612.500 | Neu | +100,0% | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 325.019 | 0 | 325.019 | 568.784 | Neu | +100,0% | |
| Quadrature Capital Ltd | 240.586 | 0 | 240.586 | 565.377 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 212.659 | 0 | 212.659 | 499.749 | Neu | +100,0% | |
| Scientech Research LLC | 211.441 | 0 | 211.441 | 496.886 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 280.650 | 283.147 | -2.497 | 491.138 | Reduziert | -0,9% | |
| Ikarian Capital, LLC | 274.978 | 274.978 | 0 | 481.212 | Unverändert | 0,0% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| B Group, Inc. | 11.414.285 | 4.500.000 | +153,7% | 19.974.999 | 8,12 |
| JANUS HENDERSON GROUP PLC | 10.689.452 | 10.540.334 | +1,4% | 18.759.988 | 7,62 |
| Octagon Capital Advisors LP | 10.276.317 | 9.567.898 | +7,4% | 17.983.555 | 7,31 |
| PERCEPTIVE ADVISORS LLC | 8.928.149 | 12.050.000 | -25,9% | 15.624.261 | 6,35 |
| AMERIPRISE FINANCIAL INC | 8.711.385 | 6.911.237 | +26,0% | 15.244.925 | 6,19 |
| Commodore Capital LP | 7.181.062 | 11.445.000 | -37,3% | 12.566.859 | 5,11 |
| RA CAPITAL MANAGEMENT, L.P. | 7.124.116 | 7.124.116 | 0,0% | 12.467.203 | 5,06 |
| FRANKLIN RESOURCES INC | 5.785.189 | 5.092.562 | +13,6% | 10.124.081 | 4,11 |
| GOLDMAN SACHS GROUP INC | 5.373.951 | 557.565 | +863,8% | 9.404.414 | 3,82 |
| Eversept Partners, LP | 4.987.499 | 5.391.548 | -7,5% | 8.728.123 | 3,55 |
| Boxer Capital Management, LLC | 4.799.875 | 4.799.875 | 0,0% | 8.399.781 | 3,41 |
| MORGAN STANLEY | 4.551.533 | 4.142.446 | +9,9% | 7.965.183 | 3,24 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.500.000 | 4.500.000 | 0,0% | 7.875.000 | 3,20 |
| GREAT POINT PARTNERS LLC | 3.405.757 | 0 | +100,0% | 5.960.075 | 2,42 |
| BALYASNY ASSET MANAGEMENT L.P. | 3.270.845 | 325.367 | +905,3% | 5.723.979 | 2,33 |
| FEDERATED HERMES, INC. | 3.136.607 | 0 | +100,0% | 5.489.062 | 2,23 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.904.911 | 0 | +100,0% | 5.083.594 | 2,07 |
| MARSHALL WACE, LLP | 2.754.403 | 0 | +100,0% | 4.820.209 | 1,96 |
| Vestal Point Capital, LP | 2.500.000 | 0 | +100,0% | 4.375.000 | 1,78 |
| ORBIMED ADVISORS LLC | 2.333.000 | 1.871.420 | +24,7% | 4.082.750 | 1,66 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 92 | 162,8 | 285 |
| 31.12.2025 | ✓ | 84 | 141,3 | 328 |
| 30.09.2025 | ✓ | 12 | 0,1 | 0 |
| 30.06.2025 | ✓ | 11 | 0,1 | 0 |
| 31.03.2025 | ✓ | 13 | 0,3 | 0 |
| 31.12.2024 | ✓ | 10 | 0,2 | 0 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| PERCEPTIVE ADVISORS LLC | 12.050.000 | 28.317.500 |
| Commodore Capital LP | 11.445.000 | 26.895.750 |
| JANUS HENDERSON GROUP PLC | 10.540.334 | 24.822.487 |
| Point72 Asset Management, L.P. | 10.495.252 | 24.663.842 |
| Octagon Capital Advisors LP | 9.567.898 | 22.484.560 |
| RA CAPITAL MANAGEMENT, L.P. | 7.124.116 | 16.741.673 |
| AMERIPRISE FINANCIAL INC | 6.911.237 | 16.241.408 |
| Eversept Partners, LP | 5.391.548 | 12.670.138 |
| FRANKLIN RESOURCES INC | 5.092.562 | 11.967.521 |
| Boxer Capital Management, LLC | 4.799.875 | 11.279.706 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| MORGAN STANLEY | 4.142.446 | 4.133.828 | +47967.4 % | 9.734.749 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.565.452 | 1.538.832 | +5780.7 % | 3.680.760 |
| UBS Group AG | 247.754 | 228.341 | +1176.2 % | 582.222 |
| BANK OF AMERICA CORP /DE/ | 70.097 | 70.011 | +81408.1 % | 164.728 |
| CITIGROUP INC | 52.281 | 49.934 | +2127.6 % | 122.860 |
| XTX Topco Ltd | 21.669 | 7.584 | +53.8 % | 50.922 |
| NFSG Corp | 15.000 | 2.000 | +15.4 % | 35.250 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 1.025 | -4.371 | -81.0 % | 2.409 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 27.05.2026 | Guy Levy | Passiv (13G) | 5,40 % | 9.353.687 | Neu | |
| 27.05.2026 | Soleus Capital Management, L.P. | Passiv (13G) | 5,40 % | 9.353.687 | Neu | |
| 27.05.2026 | Soleus GP, LLC | Passiv (13G) | 5,40 % | 9.353.687 | Neu | |
| 27.05.2026 | Soleus Capital Group, LLC | Passiv (13G) | 5,40 % | 9.353.687 | Neu | |
| 27.05.2026 | Soleus Capital, LLC | Passiv (13G) | 5,40 % | 9.353.687 | Neu | |
| 27.05.2026 | Soleus Capital Master Fund, L.P. | Passiv (13G) | 5,40 % | 9.353.687 | Neu | |
| 15.05.2026 | Commodore Capital LP | Passiv (13G/A) | 7,20 % | 12.366.776 | -2,70 pp | |
| 15.05.2026 | Michael Kramarz | Passiv (13G/A) | 7,20 % | 12.366.776 | -2,70 pp | |
| 15.05.2026 | Robert Egen Atkinson | Passiv (13G/A) | 7,20 % | 12.366.776 | -2,70 pp | |
| 15.05.2026 | Commodore Capital Master LP | Passiv (13G/A) | 7,20 % | 12.366.776 | -2,70 pp | |
| 15.05.2026 | Peter Kolchinsky | Passiv (13G/A) | 9,90 % | 17.620.479 | 0,00 pp | |
| 15.05.2026 | RA Capital Healthcare Fund, L.P. | Passiv (13G/A) | 9,90 % | 17.620.479 | 0,00 pp | |
| 15.05.2026 | RA Capital Management, L.P. | Passiv (13G/A) | 9,90 % | 17.620.479 | 0,00 pp | |
| 15.05.2026 | Rajeev Shah | Passiv (13G/A) | 9,90 % | 17.620.479 | 0,00 pp | |
| 15.05.2026 | Perceptive Life Sciences Master Fund, Ltd. | Passiv (13G/A) | 7,90 % | 14.113.863 | -2,09 pp | |
| 15.05.2026 | Joseph Edelman | Passiv (13G/A) | 7,90 % | 14.113.863 | -2,09 pp | |
| 15.05.2026 | Perceptive Advisors LLC | Passiv (13G/A) | 7,90 % | 14.113.863 | -2,09 pp | |
| 15.05.2026 | Ameriprise Financial, Inc. | Passiv (13G) | 5,30 % | 8.711.385 | Neu | |
| 15.05.2026 | Columbia Management Investment Advisers, LLC | Passiv (13G) | 5,30 % | 8.711.385 | Neu | |
| 15.05.2026 | Point72 Capital Advisors, Inc. | Passiv (13G/A) | 0,20 % | 411.772 | -6,80 pp | |
| 15.05.2026 | Point72 Asset Management, L.P. | Passiv (13G/A) | 0,20 % | 411.772 | -6,80 pp | |
| 15.05.2026 | Steven A. Cohen | Passiv (13G/A) | 0,20 % | 411.772 | -6,80 pp | |
| 17.02.2026 | Squadron Master Fund LP | Passiv (13G/A) | 3,00 % | 4.500.000 | -4,60 pp | |
| 17.02.2026 | Matthew Sesterhenn | Passiv (13G/A) | 3,00 % | 4.500.000 | -5,50 pp | |
| 17.02.2026 | Squadron Capital Management LLC | Passiv (13G/A) | 3,00 % | 4.500.000 | -5,50 pp | |
| 17.02.2026 | William Blank | Passiv (13G/A) | 3,00 % | 4.500.000 | -5,50 pp | |
| 17.02.2026 | Peter Kolchinsky | Passiv (13G/A) | 9,90 % | 15.746.829 | 0,00 pp | |
| 17.02.2026 | Rajeev Shah | Passiv (13G/A) | 9,90 % | 15.746.829 | 0,00 pp | |
| 17.02.2026 | RA Capital Management, L.P. | Passiv (13G/A) | 9,90 % | 15.746.829 | 0,00 pp | |
| 17.02.2026 | RA Capital Healthcare Fund, L.P. | Passiv (13G/A) | 9,90 % | 15.746.829 | 0,00 pp | |
| 17.02.2026 | Perceptive Life Sciences Master Fund, Ltd. | Passiv (13G/A) | 9,99 % | 15.200.117 | 0,00 pp | |
| 17.02.2026 | Perceptive Advisors LLC | Passiv (13G/A) | 9,99 % | 15.200.117 | 0,00 pp | |
| 17.02.2026 | Joseph Edelman | Passiv (13G/A) | 9,99 % | 15.200.117 | 0,00 pp | |
| 17.02.2026 | Point72 Capital Advisors, Inc. | Passiv (13G/A) | 7,00 % | 10.495.252 | +0,80 pp | |
| 17.02.2026 | Point72 Asset Management, L.P. | Passiv (13G/A) | 7,00 % | 10.495.252 | +0,80 pp | |
| 17.02.2026 | Steven A. Cohen | Passiv (13G/A) | 7,00 % | 10.495.252 | +0,80 pp | |
| 13.02.2026 | Deep Track Biotechnology Master Fund, Ltd. | Passiv (13G/A) | Ausstieg | 0 | -6,49 pp | |
| 13.02.2026 | David Kroin | Passiv (13G/A) | Ausstieg | 0 | -9,99 pp | |
| 13.02.2026 | Deep Track Special Opportunities Fund, LP. | Passiv (13G/A) | Ausstieg | 0 | -3,50 pp | |
| 13.02.2026 | Deep Track Capital, LP | Passiv (13G/A) | Ausstieg | 0 | -9,99 pp |
Stammdaten
Palisade Bio, Inc. ist ein klinisches Stadium Biopharmazeutik-Unternehmen, das sich auf die Entdeckung, Entwicklung und Vermarktung von oralen Therapien konzentriert, die auf schwere Krankheiten abzielen, die mit dem Zusammenbruch der Schleimhautbarriere verbunden sind, die den Magen-Darm-Trakt schützt. Sein führender therapeutischer Kandidat ist LB1148, eine orale Flüssigformulierung eines Verdauungsenzym-Inhibitors, die die Aktivität von Verdauungsenzymen hemmen und die Darmintegrität während des Darmstresses aufgrund von vermindertem Blutfluss zum Darm, Infektionen oder aufgrund von Chirurgie bewahren soll. Das Unternehmen wurde 2005 gegründet und hat seinen Hauptsitz in Carlsbad, Kalifornien.
Unternehmen & Branche
| Name | PALISADE BIO, INC. |
|---|---|
| Ticker | PALI |
| CIK | 0001357459 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 696389402 |
|---|---|
| ISIN | US6963894026 |
| Typ | Common Stock |
| Marktkapitalisierung | 281,2 Mio. USD |
| Beta | 1,44 |
Bewertung
| KBV (P/B) | 2,17 vs. 37,70 (2021) ▼ |
|---|---|
| FCF-Rendite | -3,9 % vs. -5,3 % (2021) ▲ |
Qualität & Bilanz
| ROIC | -13,0 % vs. -351,9 % (2021) ▲ |
|---|
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 37,70 | 18,40 | 0,48 | 0,61 | 2,90 | |
| FCF-Rendite | -5,3 % | -5,8 % | -203,6 % | -266,9 % | -2,9 % | |
| Qualität & Bilanz | ||||||
| ROIC | -351,9 % | -111,4 % | -106,7 % | -190,4 % | -13,0 % | |
| Zinsdeckungsgrad | -17,5 | – | -871,3 | – | – | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | -9.600.000 | -0,05 | 133.315.000 | 127.362.000 | |
| 2025-12-31 | 10-K | -16.781.000 | -0,30 | 134.344.000 | 129.380.000 | |
| 2025-09-30 | 10-Q | -2.868.000 | -0,38 | 6.973.000 | 3.212.000 | |
| 2025-06-30 | 10-Q | -2.784.000 | -0,58 | 6.667.000 | 2.620.000 | |
| 2025-03-31 | 10-Q | -2.230.000 | -0,47 | 8.190.000 | 5.331.000 | |
| 2024-12-31 | 10-K | 0 | -14.438.000 | -10,19 | 10.880.000 | 7.492.000 |
| 2024-09-30 | 10-Q | 0 | -3.487.000 | -2,32 | 9.336.000 | 6.608.000 |
| 2024-06-30 | 10-Q | 0 | -4.080.000 | -3,32 | 12.871.000 | 9.949.000 |
| 2024-03-31 | 10-Q | 0 | -3.527.000 | -4,59 | 12.652.000 | 10.064.000 |
| 2023-12-31 | 10-K | 250.000 | -12.300.000 | -27,01 | 14.052.000 | 11.313.000 |
| 2023-09-30 | 10-Q | 0 | -3.596.000 | -7,38 | 17.067.000 | 14.082.000 |
| 2023-06-30 | 10-Q | 0 | -3.393.000 | -7,93 | 18.290.000 | 15.800.000 |
| 2023-03-31 | 10-Q | 250.000 | -2.340.000 | -8,13 | 15.262.000 | 13.747.000 |
| 2022-12-31 | 10-K | 0 | -14.260.000 | -16,53 | 15.763.000 | 12.479.000 |
| 2022-09-30 | 10-Q | 0 | -3.991.000 | -4,10 | 16.266.000 | 12.430.000 |
| 2022-06-30 | 10-Q | 0 | -2.344.000 | -5,77 | 7.806.000 | 4.211.000 |
| 2022-03-31 | 10-Q | 0 | -4.205.000 | -12,96 | 8.350.000 | 4.792.000 |
| 2021-12-31 | 10-K | -26.616.000 | -169,74 | 12.512.000 | 7.365.000 | |
| 2021-09-30 | 10-Q | 8.087.000 | 0,42 | 16.274.000 | 3.920.000 | |
| 2021-06-30 | 10-Q | -31.746.000 | -4,10 | 14.949.000 | -9.444.000 |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 12.05.2026 | – | -0,05 |
| Q3 2025 | 30.09.2025 | 10.11.2025 | – | -0,38 |
| Q2 2025 | 30.06.2025 | 11.08.2025 | – | -0,58 |
| Q1 2025 | 31.03.2025 | 12.05.2026 | – | -0,47 |
| Q3 2024 | 30.09.2024 | 10.11.2025 | 0 USD | -2,32 |
| Q2 2024 | 30.06.2024 | 11.08.2025 | 0 USD | -3,32 |
| Q1 2024 | 31.03.2024 | 12.05.2025 | 0 USD | -4,59 |
| Q3 2023 | 30.09.2023 | 12.11.2024 | 0 USD | -7,38 |
| Q2 2023 | 30.06.2023 | 12.08.2024 | 0 USD | -7,93 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 12.05.2026 | 10-Q | – | – | SEC » |
| 20.03.2026 | 10-K | 31.12.2025 | 79 Tage | SEC » |
| 10.11.2025 | 10-Q | 30.09.2025 | 41 Tage | SEC » |
| 11.08.2025 | 10-Q | 30.06.2025 | 42 Tage | SEC » |
| 12.05.2025 | 10-Q | 31.03.2025 | 42 Tage | SEC » |
| 24.03.2025 | 10-K | 31.12.2024 | 83 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 12.08.2024 | 10-Q | 30.06.2024 | 43 Tage | SEC » |
| 13.05.2024 | 10-Q | 31.03.2024 | 43 Tage | SEC » |
| 26.03.2024 | 10-K | 31.12.2023 | 86 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 10.08.2023 | 10-Q | 30.06.2023 | 41 Tage | SEC » |
| 11.05.2023 | 10-Q | 31.03.2023 | 41 Tage | SEC » |
| 22.03.2023 | 10-K | 31.12.2022 | 81 Tage | SEC » |
| 14.11.2022 | 10-Q | 30.09.2022 | 45 Tage | SEC » |
| 15.08.2022 | 10-Q | 30.06.2022 | 46 Tage | SEC » |
| 13.05.2022 | 10-Q | 31.03.2022 | 43 Tage | SEC » |
| 17.03.2022 | 10-K | 31.12.2021 | 76 Tage | SEC » |
| 12.11.2021 | 10-Q | 30.09.2021 | 43 Tage | SEC » |
| 14.09.2021 | 10-Q/A | 30.06.2021 | 76 Tage | SEC » |
| 23.08.2021 | 10-Q | 30.06.2021 | 54 Tage | SEC » |
| 14.05.2021 | 10-Q | 31.03.2021 | 44 Tage | SEC » |
| 22.03.2021 | 10-K | 31.12.2020 | 81 Tage | SEC » |
| 10.11.2020 | 10-Q | 30.09.2020 | 41 Tage | SEC » |
| 13.08.2020 | 10-Q | 30.06.2020 | 44 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (11.06.2026)
HOCH Abgang Schlüsselpersonen (11.06.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 11.06.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 22.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 09.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 27.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 10.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 13.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 11.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 of this Current Report on Form 8-K to the extent required by this Item 1.01 is incorporated herein by… |
| 09.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 08.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.11.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.10.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.10.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 5.02 of this Current Report on Form 8-K is incorporated by reference herein in its entirety. Item 5.02. Departure of… |
| 24.02.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 23.11.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 27.04.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 of this Current Report on Form 8-K regarding the Company’s board of directors (the “Board”) and principal… |
| 02.04.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 of this Current Report on Form 8-K regarding the issuance of inducement grants in the form of options to… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-11 | 7 | 1,80 | 13 |
| 2026-05-05 | 3.506 | 2,13 | 7.468 |
| 2026-05-04 | 3.506 | 1,99 | 6.977 |
| 2026-04-29 | 47.920 | 1,95 | 93.444 |
| 2026-04-28 | 47.920 | 1,96 | 93.923 |
| 2026-03-03 | 114 | 1,81 | 206 |
| 2026-02-24 | 202 | 1,61 | 325 |
| 2026-02-11 | 4.112 | 1,73 | 7.114 |
| 2026-02-04 | 1.607 | 1,66 | 2.668 |
| 2026-01-15 | 1.207 | 1,95 | 2.354 |
| 2026-01-07 | 18.401 | 1,92 | 35.330 |
| 2025-12-31 | 71.354 | 2,36 | 168.395 |
| 2025-12-23 | 469.678 | 2,08 | 976.930 |
| 2025-12-22 | 429.780 | 1,83 | 786.497 |
| 2025-12-19 | 65 | 1,67 | 109 |
| 2025-12-16 | 1.924 | 1,81 | 3.482 |